Cantargia has provided updated interim data from its Phase IIa CANFOUR trial, reporting new efficacy data from the combination arms of the study investigating CAN04 (anti-IL1RAP) in first-line NSCLC and PDAC. These new Phase IIa data, combined with initial interim data reported in December 2019, continue to support the hypothesis that CAN04 has a synergistic benefit with chemotherapy, in our view. Another tailwind is increasing positive sentiment on Novartis’s canakinumab (anti-IL1beta) progress ....
30 Oct 2020
Cantargia - Buoyant on CANFOUR and CANOPY interims
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cantargia - Buoyant on CANFOUR and CANOPY interims
Cantargia has provided updated interim data from its Phase IIa CANFOUR trial, reporting new efficacy data from the combination arms of the study investigating CAN04 (anti-IL1RAP) in first-line NSCLC and PDAC. These new Phase IIa data, combined with initial interim data reported in December 2019, continue to support the hypothesis that CAN04 has a synergistic benefit with chemotherapy, in our view. Another tailwind is increasing positive sentiment on Novartis’s canakinumab (anti-IL1beta) progress ....